The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...

The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

Like other developing countries, Indonesia is facing a familiar dilemma: how to feed a growing population while protecting ...

Baby KJ was the first to receive a bespoke gene-editing treatment. Personalized drugs for others could be approved within the ...

Cathie Wood’s latest moves entering 2026 focused on early-stage biotechnology firms while cutting exposure to consumer ...

Gene editing is now reaching the mainstream, ushering in a new era of genetic manipulation. Traditionally, inserting or deleting entire genes, regulating their expression, and altering specific ...

He Jiankui spent three years in prison after creating gene-edited babies. Now back at work, he sees a greater opening for ...

Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.